Emmanuel Di Paolo
Overview
Explore the profile of Emmanuel Di Paolo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
383
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ysebaert C, Castado C, Mortier M, Rioux S, Feron C, Di Paolo E, et al.
Vaccine
. 2021 Aug;
39(39):5641-5649.
PMID: 34446318
Moraxella catarrhalis (Mcat) is a key pathogen associated with exacerbations of chronic obstructive pulmonary disease (COPD) in adults and playing a significant role in otitis media in children. A vaccine...
2.
Stadtmauer E, Sullivan K, El Idrissi M, Salaun B, Alonso Alonso A, Andreadis C, et al.
Hum Vaccin Immunother
. 2021 Aug;
17(11):4144-4154.
PMID: 34406911
Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses...
3.
Boutry C, Hastie A, Diez-Domingo J, Tinoco J, Yu C, Andrews C, et al.
Clin Infect Dis
. 2021 Jul;
74(8):1459-1467.
PMID: 34283213
Background: This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV)...
4.
Feyssaguet M, Berthold V, Helle L, Povey M, Ravault S, Carryn S, et al.
Vaccine
. 2020 Mar;
38(17):3300-3304.
PMID: 32184033
Antibody response against varicella-zoster virus (VZV) is frequently assessed by whole-virus- (anti-VZV) or glycoprotein-based ELISAs. This study compared antibody concentrations measured by an assay quantifying anti-VZV glycoprotein E (anti-gE) and...
5.
Dagnew A, Klein N, Herve C, Kalema G, Di Paolo E, Peterson J, et al.
J Infect Dis
. 2020 Feb;
224(7):1139-1146.
PMID: 32103273
Background: Efficacy of the live-attenuated herpes zoster (HZ) vaccine (ZVL) wanes substantially over time. We evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous ZVL recipients....
6.
Dagnew A, Ilhan O, Lee W, Woszczyk D, Kwak J, Bowcock S, et al.
Lancet Infect Dis
. 2019 Aug;
19(9):988-1000.
PMID: 31399377
Background: The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem cell transplant recipients. We evaluated the safety and immunogenicity of this vaccine...
7.
Carryn S, Feyssaguet M, Povey M, Di Paolo E
Vaccine
. 2019 Jul;
37(36):5323-5331.
PMID: 31345639
Measles and mumps outbreaks still occur in countries that have successfully implemented universal routine immunization programs. Measles outbreaks are mostly associated to absent or incomplete vaccination, whereas for mumps outbreaks...
8.
Ravault S, Friel D, Di Paolo E, Caplanusi A, Gillard P, Povey M, et al.
J Infect Dis
. 2019 Jul;
220(9):1462-1468.
PMID: 31299077
Background: The plaque reduction neutralization test (PRNT), which measures a subset of immunoglobulin antibodies (functional neutralizing antibodies), and the enzyme-linked immunosorbent assay (ELISA), which measures total immunoglobulin (neutralizing and nonneutralizing...
9.
Van Damme P, Dionne M, Leroux-Roels G, Van Der Meeren O, Di Paolo E, Salaun B, et al.
J Viral Hepat
. 2019 May;
26(9):1066-1075.
PMID: 31087382
The duration of protection after hepatitis B vaccination is not exactly known. This phase IV study evaluated antibody persistence and immune memory 20-30 years after adult immunization with recombinant hepatitis...
10.
Vink P, Ramon Torrell J, Sanchez Fructuoso A, Kim S, Kim S, Zaltzman J, et al.
Clin Infect Dis
. 2019 Mar;
70(2):181-190.
PMID: 30843046
Background: The incidence of herpes zoster is up to 9 times higher in immunosuppressed solid organ transplant recipients than in the general population. We investigated the immunogenicity and safety of...